Brain Abscess Following CPX‐351 Treatment in a Patient With Acute Myeloid Leukemia Authors: Yusuke Yamaga, Shoichiro Okazaki, Yuri Sakuma, Daimon Siraisi, Takahiro Nishiyama, Kalyani Sen Published: 2026 ABSTRACT AbstractWe describe a rare case of a brain abscess occurring during CPX‐351 induction therapy for acute myeloid leukemia (AML). The patient experienced recurrent febrile neutropenia during the myelosuppression period and developed left‐sided spatial neglect during hematologic recovery. Brain magnetic resonance imaging revealed a solitary abscess in the right parietal lobe. Burr hole drainage yielded Bacillus species, and subsequent treatment with vancomycin and linezolid, followed by endoscopic abscess resection, led to gradual neurological recovery. Complete remission of AML was achieved, and consolidation therapy with venetoclax plus azacitidine was initiated. CPX‐351 is associated with prolonged myelosuppression and relatively low gastrointestinal toxicity, which may reduce the risk of Gram‐negative sepsis but increase susceptibility to Gram‐positive infections, such as catheter‐related bacteremia. Clinicians should consider the possibility of a brain abscess in patients presenting with neurological symptoms during AML treatment, as early diagnosis and prompt surgical and antimicrobial management are critical for favorable outcomes.Keywords: acute myeloid leukemia, Bacillus cereus, brain abscess, CPX-351, immunocompromised patients 1. Introduction CPX‐351, a liposomal formulation of daunorubicin and cytarabine, has emerged as an important induction regimen for acute myeloid leukemia (AML) with myelodysplasia‐related changes (AML–MRC), particularly among older adults and patients with therapy‐related AML [1]. Compared with conventional intensive chemotherapy, CPX‐351 is associated with lower gastrointestinal toxicity, potentially reducing the risk of Gram‐negative bacteremia secondary to mucosal barrier injury [2]. However, it induces prolonged and profound myelosuppression, increasing susceptibility to severe infections, particularly those caused by Gram‐positive organisms, such as catheter‐related bloodstream infections (CRBSIs) [3]. Central nervous system (CNS) infections during AML treatment are uncommon, and brain abscesses are particularly rare and challenging to diagnose or manage. Reported pathogens include Bacillus cereus [4–6], fungal species such as Aspergillus and Mucorales [7, 8], and, more rarely, Acanthamoeba [9]. These infections often lead to considerable neurological deficits and can be fatal. Although advances in antimicrobial therapy and surgical techniques have improved survival in some cases, early diagnosis and prompt intervention remain crucial [10]. Here, we report a rare case of a brain abscess caused by Bacillus species in a patient receiving CPX‐351 induction therapy for AML–MRC. This case underscores the importance of early recognition and individualized management of CNS infections due to atypical pathogens during profound immunosuppression. 2. Case Presentation A 60‐year‐old Japanese man was evaluated for pancytopenia. His medical history included Type 2 diabetes mellitus, myocardial infarction treated with percutaneous coronary intervention, abdominal aortic aneurysm, and resolved hepatitis B infection. His regular medications included magnesium oxide, carvedilol, rabeprazole, clopidogrel, linaclotide, and telmisartan. He had no known drug allergies and had smoked 20 cigarettes daily from age 20–42 years but had since quit. Laboratory tests showed a white blood cell count (WBC) of 900/µL, absolute neutrophil count (ANC) of 153/µL, hemoglobin level of 6.7 g/dL, platelet count of 57,000/µL, and C‐reactive protein level of 0.03 mg/dL. Bone marrow aspiration revealed hypercellular marrow with dysplasia in all three lineages and myeloblasts positive for myeloperoxidase (MPO), negative for CD34, and positive for c‐Kit—findings consistent with AML–MRC (Figure 1). The patient was admitted and started on induction chemotherapy with CPX‐351 (Day 1). On Day 14, he developed febrile neutropenia (FN), and cefepime therapy was initiated. Staphylococcus epidermidis was isolated from catheter‐drawn blood cultures earlier than from peripheral samples, indicating a CRBSI. The central venous catheter was removed, and vancomycin was added but discontinued on Day 17 based on susceptibility results. (a, b) Bone marrow smear showing hypercellularity (May–Grünwald–Giemsa stain, × 10). Higher magnification (× 100) reveals myeloblasts negative for CD34 and positive for CD117 (c‐Kit) by flow cytometry. (c) Karyotypic analysis showing 46, XY (20/20 cells). On Day 29, FN recurred with radiological evidence of pneumonia. Meropenem, liposomal amphotericin B (L‐AMB), and granulocyte colony‐stimulating factor (G‐CSF) were initiated. By Day 38, hematologic recovery was noted (WBC 3200/µL, ANC 2336/µL, hemoglobin 9.9 g/dL, and platelets 76,000/µL). However, the patient developed new‐onset left hemispatial neglect. Brain MRI revealed a solitary abscess measuring 30 × 50 × 43 mm in the right parietal lobe. The behavioral inattention test (BIT) score was 60/146. Burr hole drainage was performed the same day, and high‐dose meropenem in combination with vancomycin was administered. Considering CNS penetration, antifungal therapy was switched from L‐AMB to voriconazole. Culture of the abscess fluid yielded Bacillus species, and vancomycin administration was continued (Table 1). TABLE 1Summary of the patient’s clinical course, causative pathogens, and antibiotic susceptibility. CRBSI Pneumonia Brain abscess Onset of infectionDay 15Day 29Day 38Causative bacteria Staphylococcus epidermidisNormal flora Bacillus speciesAntibiotic susceptibilitySensitive to all antibiotics—Unable to identify Summary of the patient’s clinical course, causative pathogens, and antibiotic susceptibility. On Day 45, a second burr hole drainage was performed because of a persistent abscess. As the lesion showed no improvement, vancomycin was replaced with oral linezolid on Day 51. Endoscopic abscess removal was performed on Day 52, resulting in gradual reduction in abscess size. Neurological symptoms improved progressively after initiation of linezolid therapy, with BIT scores increasing to 130/146 on Day 63 and 140/146 on Day 84. Linezolid therapy was completed on Day 93, and the patient was subsequently discharged (Figure 2). Timeline of the clinical course. BIT, behavioral inattention test; FCZ, fluconazole; L‐AMB, liposomal amphotericin B; VRCZ, voriconazole; CFPM, cefepime; MEPM, meropenem; VCM, vancomycin; LZD, linezolid. The patient achieved complete remission of AML following CPX‐351 induction. WT1 mRNA levels in peripheral blood, which had been 4.3 × 103 copies/µg RNA at baseline, became undetectable. After confirming radiological resolution of the brain abscess, consolidation therapy with venetoclax plus azacitidine was initiated. 3. Discussion Brain abscess is a rare but potentially fatal complication in patients with AML, particularly during periods of profound immunosuppression caused by intensive chemotherapy. Since the 2000s, only a few cases have been reported (Table 2). Among the identified pathogens, Bacillus cereus is relatively common, typically emerging during the neutropenic phase and often leading to rapid clinical deterioration [4–6]. Although many cases have been fatal, some patients have survived with aggressive multimodal treatment, including surgical drainage and the administration of CNS‐penetrating antibiotics such as linezolid [6]. TABLE 2Reported cases of brain abscess during AML treatment since 2000, including pathogens, presumed routes of infection, therapeutic strategies, surgical interventions, and clinical outcomes.RefYearAge/sexUnderlying AMLPathogenRoute of infectionTherapySurgeryOutcomeSakai et al. [4]200167/FALL B. cereus Intestinal tractVCM + LVFXBurr holeSurvivedKuwabara et al. [5]200654/FAML B. cereus Catheter‐relatedMEPM + VCMNoneSurvivedKoizumi et al. [6]202054/FAML B. cereus Not clearMEPM + VCM + LZDNoneSurvivedShariati et al. [7]2021VariousAML/post‐HSCT Aspergillus Sinus/lungAMPH‐B, VRCZMixedMixedda Silveira et al. [8]202456/MAML Mucorales GI disseminationAMPH‐BNoneDiedNampoothiri et al. [9]201819/MAML Acanthamoeba Not clearST + RFP + AZMSurgerySurvivedCavazza et al. [10]202448/FAML Not specified LungMEPM + ISCZ + PSLMultisurgerySurvivedThis case202560/MAML‐MRC (CPX‐351) Bacillus spp. Catheter‐relatedVCM → LZD + VRCZBurr hole + endoscopySurvived Note: Most reported cases occurred during induction therapy or profound neutropenia, emphasizing this period as a high‐risk phase for brain abscess in patients with AML. Reported cases of brain abscess during AML treatment since 2000, including pathogens, presumed routes of infection, therapeutic strategies, surgical interventions, and clinical outcomes. Note: Most reported cases occurred during induction therapy or profound neutropenia, emphasizing this period as a high‐risk phase for brain abscess in patients with AML. Fungal brain abscesses, particularly those caused by Aspergillus species, also present major therapeutic challenges in AML patients, and voriconazole has demonstrated efficacy in selected cases [7]. Infections due to Mucorales or Acanthamoeba are rare but are typically associated with poor outcomes [8, 9]. The differential diagnosis of new‐onset neurological symptoms during induction therapy is broad and includes leukemic infiltration, cerebral hemorrhage or infarction, drug‐induced leukoencephalopathy (particularly from high‐dose cytarabine), meningitis, and other CNS infections [10]. Importantly, newly developed focal neurological deficits during neutrophil recovery should prompt immediate neuroimaging, even when systemic signs of infection appear to be improving. Serious CNS complications may emerge during apparent marrow recovery and can be underestimated if attention is focused only on hematologic improvement. This case highlights the occurrence of a brain abscess caused by Bacillus species following CPX‐351 induction therapy. CPX‐351 is known to induce prolonged neutropenia with relatively low gastrointestinal toxicity compared with conventional “7 + 3” regimens [2]. Although this pharmacologic profile may reduce the risk of gut translocation of Gram‐negative bacilli, prolonged neutropenia may preferentially predispose patients to Gram‐positive bloodstream infections, particularly catheter‐related infections, which can subsequently lead to deep‐seated complications such as a brain abscess. Our patient first developed CRBSI and later presented with a brain abscess during apparent hematologic recovery, highlighting a potential diagnostic pitfall. Management of brain abscesses in immunocompromised patients generally requires a multimodal and multidisciplinary approach involving neurosurgery, infectious disease expertise, and timely radiologic assessment [11, 12]. Antibiotic therapy alone is often insufficient; surgical drainage or resection is usually necessary for diagnostic confirmation and effective source control [4, 7, 10, 11]. In the present case, vancomycin was replaced with linezolid because of persistent radiological disease and the superior CNS penetration of linezolid, rather than because of microbiological resistance alone. Repeated burr hole drainage followed by endoscopic abscess resection, combined with appropriate antimicrobial therapy, achieved successful infection control and progressive neurological recovery. In summary, clinicians should consider brain abscess as a differential diagnosis in AML patients receiving CPX‐351 who develop new‐onset neurological symptoms. Early recognition, combined with prompt surgical and medical intervention, is crucial for improving outcomes and ensuring successful continuation of leukemia‐directed therapy. 4. Conclusion This case highlights a brain abscess as a rare but serious complication during CPX‐351 treatment for AML–MRC. Clinicians should be aware that focal neurological symptoms may emerge even during apparent hematologic recovery, and prompt neuroimaging with timely multidisciplinary management is essential for favorable outcomes. Author Contributions Treating physicians: Yusuke Yamaga, Yuri Sakuma, and Daimon Siraisi. Project administration and supervision: Takahiro Nishiyama. Validation and writing: Yusuke Yamaga. Funding This study received no specific funding. Disclosure All authors have read and approved the final version of the manuscript. Dr. Yusuke Yamaga had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. Ethics Statement According to the ethical guidelines for medical and biological research involving human subjects in Japan, the Ichinomiya Municipal Hospital Clinical Research Review Committee does not require ethical approval for a case report. Consent Written informed consent for publication was not obtained. However, this case report has been fully anonymized in accordance with the ICMJE guidelines, and no identifiable personal information is included. The publication of this case was reviewed and approved by the Ethics Committee of Ichinomiya Municipal Hospital. Conflicts of Interest The authors declare no conflicts of interest. Yamaga, Yusuke , Okazaki, Shoichiro , Sakuma, Yuri , Siraisi, Daimon , Nishiyama, Takahiro , Brain Abscess Following CPX‐351 Treatment in a Patient With Acute Myeloid Leukemia, Case Reports in Hematology, 2026, 3668400, 5 pages, 2026. 10.1155/crh/3668400 Academic Editor: Kalyani Sen Contributor Information Yusuke Yamaga, Email: yamaga-y@ichinomiya.hospital. Kalyani Sen, Email: kasen@wiley.com. Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.